Stockreport

Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF THE WOODLANDS, Texas, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) (“Repros” or the “Company”) today announced that following an Oral Expla [Read more]